Our Story
Advancing the Future of Gut Mucosal-Immune Medicine
32 Biosciences is focused on gastrointestinal (GI) diseases—initially centered on the colon—addressing high unmet medical needs in prevention and treatment with a first-in-class therapeutic and a novel discovery platform.
A compromised gastrointestinal mucosal barrier is linked to infection risk, chronic disease, and microbiome imbalance. To prevent and treat disease, we are restoring and protecting the GI mucosal-immune system while building a proprietary GI discovery platform.
- CS Therapeutic Pipeline — a Mucosal Immune Modulator (MIM) therapeutic approach that restores and protects the mucosal-immune barrier in the gastrointestinal tract (lead asset: CS-0003).
- GB: GI Discovery Platform — quantifies metabolomic signatures of the gut mucosal-immune system to enable therapeutic discovery, development, and clinical decision support.
Our mission is to prevent and treat severe GI diseases by restoring and protecting the GI mucosal-immune system and advancing our therapeutic pipeline and GI discovery platform.
Our name, 32 Biosciences (pronounced three squared), reflects our commitment to exponential progress – bringing multidisciplinary innovation together to advance gut mucosal-immune science.
Why We Exist
32 Biosciences was founded to address a critical gap in gastrointestinal medicine: today’s tools and therapies do not address the biology that drives GI disease. Surgical infections, chronic inflammation, and recurrent conditions arise when the gut mucosal-immune barrier becomes destabilized — yet existing interventions do not restore this barrier or measure gut microbiome function.
Our team came together with a unified vision: to pioneer solutions that restore and protect the gut mucosal-immune system and make the functional state of the gut measurable, actionable, and central to patient care.
Our Mission
Our mission is to restore gut mucosal-immune health and deliver metabolomic and data-driven insights that accelerate therapeutic discovery, improve patient outcomes, and transform standards of care across high-burden GI diseases.
We envision a future where:
- GI surgical site infections are fullypreventable
- Chronic inflammatory diseases are intercepted earlier
- Recurrence risks are reduced
- Screening tools guide decision-making
- Therapies restore mucosal-immune stability
Above all, we aim to deliver solutions that provide predictability, protection, and better outcomes at the moments patients need them most.
Our name, 32 Biosciences (pronounced three squared), reflects our commitment to exponential progress – bringing multidisciplinary innovation together to advance gut mucosal-immune science.